Search results for Rhhby

Roche Holding AG (RHHBY) Q1 2026 Sales/Trading Call Transcript

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Analyst Report: Roche Holding AG

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Recursion Pharmaceuticals May Be Losing Ground To Its Peers

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership

<![CDATA[Haisco Enters $745 Million Exclusive License Agreement with AbbVie ]]>

Beigene

Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

Beigene

Beigene Anonymous (not verified) Thu, 04/30/2026 - 14:18 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...

StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Trung Huynh, an analyst with RBC Capital Markets, has projected Foundayo will reach peak-year sales of $36 billion—14% above the $31.68 billion racked up by last year’s best sellin...

Analyst Report: Bristol-Myers Squibb Co

Analyst Report: Bristol-Myers Squibb Co

Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts

Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China’s R&D speed

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. Th...

RBC Capital Lifts PT on CG Oncology (CGON), Calls PIVOT-006 a Complex Catalyst

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Protalix: Elfabrio Struggles Against Oral Competition

<![CDATA[Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement]]>

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration

Behind BMS' focus on top-tier growth, as with other pharma giants, is a quest to recoup the billions of dollars in sales it stands to lose as aging blockbuster drugs head for the p...

Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B

Bristol Myers Squibb is paying $600 million up front to begin a 13-drug collaboration with Hengrui Pharma spanning oncology, hematology, and immunology. That tops a 12-drug pact GS...

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.